Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 6/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.36 |
| ▸ | WNT1 | P04628 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | WNT3A | P56704 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776099 | 0.89 | FGFR4 (0.40) | FGFR4WNT1DYRK1AMET | |
| SCHEMBL16775866 | 0.86 | FGFR4 (0.45) | FGFR4TRPV1NPY5RWNT3A | |
| SCHEMBL19365462 | 0.85 | FGFR4 (0.42) | FGFR4TRPV1WNT1DYRK1APRKCA | |
| SCHEMBL16775850 | 0.85 | FGFR4 (0.44) | FGFR4NPY5RCSF1RMETKDR | |
| SCHEMBL16775936 | 0.84 | FGFR4 (0.43) | FGFR4NPY5RCNR1 | |
| SCHEMBL16776098 | 0.84 | FGFR4 (0.43) | FGFR4WNT3ACNR1KDR | |
| SCHEMBL16775857 | 0.83 | FGFR4 (0.44) | FGFR4TRPV1 | |
| SCHEMBL16776049 | 0.83 | FGFR4 (0.42) | FGFR4TRPV1CNR1CSF1RMET | |
| SCHEMBL16776004 | 0.83 | FGFR4 (0.42) | FGFR4GSK3B | |
| SCHEMBL16776101 | 0.82 | WDR5 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | FGFR4 1754/4885TRPV1 3670/4885WNT1 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.